Arbutus Biopharma (ABUS) Receivables - Net (2009 - 2026)

Arbutus Biopharma's Receivables - Net history runs 18 years deep, the most recent figure standing at $178.7 million for Q1 2026.

• In Q1 2026, Receivables - Net rose 15021.91% year-over-year to $178.7 million; the TTM figure through Mar 2026 stood at $178.7 million (up 15021.91% YoY), while the FY2024 annual figure was $2.4 million, up 35.64% from the prior year.
• Receivables - Net came in at $178.7 million for Q1 2026 at Arbutus Biopharma, up from $905000.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $178.7 million in Q1 2026 to a low of $905000.0 in Q3 2025.
• A 5-year average of $12.8 million and a median of $1.8 million in 2022 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net sank 44.74% in 2025 and jumped 15021.91% in 2026, its largest moves.
• Arbutus Biopharma's Receivables - Net stood at $1.4 million in 2022, then jumped by 31.36% to $1.8 million in 2023, then soared by 35.64% to $2.4 million in 2024, then plunged by 62.43% to $905000.0 in 2025, then jumped by 19650.39% to $178.7 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $178.7 million, $905000.0, and $1.0 million for Q1 2026, Q3 2025, and Q2 2025 respectively.

Peer Comparison